首页 > 文献资料
-
Objective: To evaluate the myocardial protecting effect of Shenmai injection (SMI) against ischemia/reperfusion injury in thrombolytic therapy with urokinase (UK) for acute myocardial infarction patients by 99mTc-MIBI myocardial imaging (SPECT). Methods: Five hundred and thirty-seven patients were divided into two groups randomly. The SMI group (n=292) was treated with thrombolytictreatment plus SMI and the control group (n=245) with thrombolytic treatment solely. Single photon emission computed tomography (SPECT) was carried out on the 7th day after thrombolysis to determine the ischemic myocardial area (IMA) and ejection fraction (EF) in both groups and compared. Results: The infarction related area (IRA) of reperfusion rate in the two groups was not different significantly (72.26% vs 72.65%, P >0.05). The IMA in patients of the SMI group, no matter with or without reperfused IRA (211 cases and 81 cases) respectively, was significantly lower than that in the control group (178 cases and 67 cases) respectively, P<0.01 and P<0.05 respectively. The EF value in the SMI group was significantly higher than that in the control group (P<0.01). Conclusion:Using SMI in early stage of thrombolytic treatment in acute myocardial infarction could significantly reduce IMA and increase EF. SMI showed good protective effect against myocardial ischemia/reperfusion injury in thrombolytic treatment.
-
参麦注射液对急性白血病化疗患者骨髓造血功能保护作用的研究
骨髓造血功能受抑、全血细胞减少是急性白血病患者接受强烈化疗的常见并发症.2001年11月-2003年12月我院血液科对129例急性白血病患者接受大剂量联合化疗的同时给予参麦注射液治疗,并与合用维生素C和维生素B6治疗的102例作对照,现报道如下.
-
参麦注射液引起发热反应2例
随着中药制剂在临床上的广泛应用,其不良反应的报道也日益增多~([1,2]).参麦注射液有发生过敏反应的报道,但尚未发现引起发热的报道.
-
参麦注射液对慢性肺心病治疗作用的观察及对其免疫功能的影响
参麦注射液治疗慢性肺心病作用明确[1],我们于2000-01~2000-07采用参麦注射液治疗慢性肺心病病人64例,观察其对血液免疫球蛋白影响,现报道如下.